ASND today
$267.07+$7.79 (+3.00%)close Nov 12, 2026Trend
DailyUptrend (starting)
4 hourStrong Bullish
1 hourBullish
15 minLeaning Bearish
5 minConsolidating
Daily trend turns down below $203.80
Key levels
Resistance$282.15
Resistance$272.47
Support$262.02
Support$255.61
Latest news & SEC filings
EarningsAscendis Pharma holds Q3 2026 earnings call
EarningsAscendis Pharma Posts Q3 2026 Financials
EarningsAscendis Pharma Q3 adjusted EPS $1.97, sales $425.432M, both above estimates
All ASND news →About Ascendis Pharma
Ascendis Pharma is a biopharmaceutical company that develops therapies using its TransCon technology platform, which is designed to create long-acting versions of drugs. Its approved products include SKYTROFA for growth hormone deficiency and YORVIPATH for hypoparathyroidism, both sold in the United States and Europe. The company also has development programs in endocrinology rare diseases and oncology. It operates in the U.S. and Europe and sells to patients, physicians, and healthcare payors.
Based on the company's 20-F filed Feb 11, 2026.
Nasdaq · Healthcare
Ascendis Pharma A/S (ASND)
What Is the Price Target for ASND?
SEPT Low Target
$273.00
SEPT Mid Target
$326.00
SEPT High Target
$355.00
Analyst Consensus
$326.00
Is ASND a Buy or Sell Right Now?
Thesis
- •Revenue growing 106.6% YoY with STRONG trend — consistent growth.
- •SEC filings signal active product innovation — 2 new product/expansion keywords detected in 10-K. R&D investment rising.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for ASND.
Start Free Trial →Is ASND Overvalued or Undervalued?
Valuation Verdict
FAIR
Methods Used
P/E Forward, Analyst Consensus
Fair Value
$308.61
48
Moat Score
NARROW
4/9
Piotroski Score
5.7
Altman Z-Score
What Is Smart Money Doing with ASND?
Insider Signal
BUYING
5 buys / 1 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
MEDIUM
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| SMITH SCOTT THOMAS | officer | Buy | 100 | $22K | Jun 2, 2026 |
| BIENAIME JEAN JACQUES | director | Buy | 200 | $45K | May 29, 2026 |
| BIENAIME JEAN JACQUES | director | Buy | 100 | $22K | May 29, 2026 |
| SMITH SCOTT THOMAS | officer | Buy | 250 | $56K | May 29, 2026 |
| BIENAIME JEAN JACQUES | director | Buy | 200 | $47K | May 26, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →ASND Growth Story
Revenue YoY
106.6%
3yr Revenue CAGR
147.2%
EPS Growth YoY
39.93%
FCF Growth YoY
N/A%
Revenue Trend
STRONG
Dark Pool Trades for ASND
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for ASND, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:58:56 | $267.07 | 39,695 | $$10.6M | BUY |
| 21:00:14 | $267.07 | 2,119 | $$566K | BUY |
| 21:00:00 | $267.07 | 5,064 | $$1.4M | SELL |
| 19:09:03 | $267.08 | 1,577 | $$421K | MIDPOINT |
| 18:54:01 | $264.24 | 1,439 | $$380K | BUY |
5 dark pool trades shown · $$13.3M preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for ASND
PREVIEWSEPT Investing provides real-time options flow tracking for ASND, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| PUT | $370 | Nov 20 | 8 | $$10.6K | 1 | SWEEP |
| PUT | $370 | Nov 20 | 8 | $$10.6K | 1 | SWEEP |
| PUT | $380 | Nov 20 | 8 | $$11.6K | 1 | SWEEP |
| PUT | $380 | Nov 20 | 8 | $$11.6K | 1 | SWEEP |
| PUT | $360 | Nov 20 | 8 | $$9610 | 1 | SWEEP |
5 options trades shown · 0% calls
Unusual activity, GEX levels, max pain, and dealer positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Ascendis Pharma A/S (ASND) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (3 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →ASND — frequently asked questions
What is ASND stock price today?
Ascendis Pharma A/S (ASND) is at $267.07, up 3.00% (+$7.79) at the Nov 12, 2026 close.
Why is ASND stock up today?
Nov 12, 2026: Ascendis Pharma reported third-quarter 2026 adjusted earnings per share of $1.97 and sales of $425.432 million, both exceeding analyst estimates of $1.13 per share and $417.230 million. The company also held its Q3 2026 earnings call and disclosed its financial performance for the period.
What is the ASND price target?
The average analyst price target for ASND is $326.00, ranging from $273 to $355, based on 15 analysts. Latest: Raymond James downgrade on Sep 15, 2026.
What do analysts rate ASND?
Analyst ratings for ASND: 0 Buy, 18 Hold, 2 Sell — consensus Hold.
Did ASND beat earnings?
ASND last reported on Nov 12, 2026: EPS $1.97 vs $1.13 expected — a beat of 74.3%.
Does ASND pay a dividend?
ASND does not currently pay a dividend.
How much debt does ASND have?
Ascendis Pharma A/S reported $845M of debt and $723M of cash (Dec 31, 2025).
What are ASND support and resistance levels?
Support: $262.02, $255.61, $248.31. Resistance: $272.47, $282.15.
What are insiders doing with ASND?
Insider activity: BUYING, 5 buys and 1 sells in the last 90 days.
What is the latest news on ASND?
Nov 12, 2026: Ascendis Pharma holds Q3 2026 earnings call · Nov 12, 2026: Ascendis Pharma Posts Q3 2026 Financials · Nov 12, 2026: Ascendis Pharma Q3 adjusted EPS $1.97, sales $425.432M, both above estimates